CSNK1G1/CSNK1G2/CSNK1G3 Antibody

What applications are CSNK1G antibodies suitable for in laboratory research?

CSNK1G antibodies are validated for multiple research applications including:

• Western Blotting (WB)

• Immunohistochemistry (IHC) for both paraffin-embedded and frozen sections

• Immunoprecipitation (IP)

• ELISA

• Immunofluorescence (IF)/Immunocytochemistry (ICC)

The optimal application depends on the specific antibody clone and host. For example, the monoclonal CSNK1G1 antibody clone 3F10 has been rigorously validated for Western Blot, ELISA, and RNAi knockdown verification , while the polyclonal CSNK1G3 antibody has been validated for Western Blot and IHC applications .

What is the typical tissue distribution pattern of CSNK1G proteins?

The expression pattern of CSNK1G proteins varies across tissues:

CSNK1G2 is particularly highly expressed in the seminiferous tubules of the testis and overlaps with RIPK3 expression in spermatogenic cells and Sertoli cells . When considering antibody selection for your experiment, tissue-specific expression patterns should inform your choice of control samples.

How should I validate the specificity of CSNK1G antibodies?

To ensure antibody specificity:

• Use knockout (KO) or knockdown (KD) controls when possible. For instance, CSNK1G2-knockout mice showed no detection of CSNK1G2 protein in testis tissue, confirming antibody specificity .

• Include both positive and negative controls in Western blot analysis:

  • Positive control: Transfected lysate overexpressing the target protein

  • Negative control: Non-transfected lysate or knockout cell samples

• Validate with RNAi knockdown: Compare Western blot results between cells co-transfected with CSNK1G-specific siRNA and non-transfected controls .

• Cross-reactivity testing: If studying one CSNK1G isoform, check for cross-reactivity with other isoforms, especially given the sequence similarity between CSNK1G1, CSNK1G2, and CSNK1G3.

How can I design experiments to investigate interactions between CSNK1G proteins and their binding partners?

To study protein-protein interactions involving CSNK1G proteins:

• Co-immunoprecipitation (Co-IP):

  • Express tagged versions of CSNK1G (e.g., FLAG-tagged) and its potential binding partner (e.g., HA-tagged)

  • Immunoprecipitate using anti-tag antibodies

  • Detect co-precipitated proteins by Western blot

This approach has been successfully used to demonstrate interaction between CSNK1G2 and RIPK3 , as well as between CSNK-1 (C. elegans ortholog) and DOXA-1 .

• Pull-down assays with purified proteins:

  • Express and purify His-tagged fusion proteins (e.g., His::TF::CSNK-1)

  • Incubate with cell lysates containing the potential binding partner

  • Perform pull-down and analyze by Western blot

• Reverse approaches:

  • Immunoprecipitate the endogenous CSNK1G from tissue extracts

  • Detect co-precipitated proteins by Western blot or mass spectrometry

For example, endogenous CSNK1G2 immunoprecipitated from mouse testis extracts co-precipitated with endogenous RIPK3, confirming their interaction in vivo .

What are the critical considerations when using CSNK1G antibodies for studying their role in necroptosis?

When investigating CSNK1G's role in necroptosis:

• Select appropriate cell death assays:

  • Use multiple necroptosis-inducing agents (T/S/Z, TRAIL/S/Z, LPS/S/Z) to confirm specificity

  • Include proper controls (e.g., RIPK3 knockout cells as negative control)

• Consider the dual role of kinase activity:

  • The kinase activity of CSNK1G2 is required for suppressing RIPK3 kinase activity

  • Kinase-dead mutants (CSNK1G2(K75A) and CSNK1G2(D165N)) fail to suppress RIPK3

• Assess phosphorylation status:

  • Monitor RIPK3 serine 227 auto-phosphorylation as a measure of RIPK3 kinase activity

  • Track downstream phosphorylation of MLKL, which is critical for necroptosis execution

• In tissue studies:

  • For testis aging studies, use phospho-MLKL as a necroptosis activation marker

  • Compare young vs. old tissue samples when studying age-related changes

How can I troubleshoot inconsistent Western blot results when using CSNK1G antibodies?

When facing inconsistent Western blot results:

• Sample preparation issues:

  • Ensure complete protein denaturation for detecting transmembrane domains

  • Use phosphatase inhibitors to preserve phosphorylation status

  • Consider tissue-specific extraction protocols (particularly for testis samples)

• Antibody-specific considerations:

  • Different antibodies may recognize different epitopes or isoforms

  • Check if your antibody recognizes a specific phosphorylated form

  • For CSNK1G1 antibodies, confirm which amino acid region they target (e.g., AA 293-393 vs. AA 1-125)

• Detection sensitivity:

  • For low-expression tissues, increase protein loading or use enhanced chemiluminescence substrates

  • Consider immunoprecipitation before Western blot for enrichment

• Molecular weight verification:

  • CSNK1G1: Expected at approximately 49 kDa

  • Post-translational modifications may affect migration pattern

  • Auto-phosphorylation (e.g., at serine 211/threonine 215 sites in CSNK1G2) may alter mobility

What experimental approaches are recommended for investigating the role of CSNK1G in oxidative stress response?

To study CSNK1G in oxidative stress responses:

• Genetic interaction studies:

  • Use genetic nonallelic noncomplementation assays to identify interactions (e.g., between csnk-1 and bli-3/tsp-15/doxa-1 genes in C. elegans)

  • Consider double knockout designs comparing single and double mutants

• ROS measurement techniques:

  • Use fluorescent ROS indicators to measure cellular ROS levels

  • Compare ROS levels in wild-type versus CSNK1G knockout/knockdown cells

• Pharmacological approaches:

  • Apply casein kinase 1 inhibitors to assess effects on ROS levels

  • Use oxidative stress-inducing agents to challenge cells

• Conservation analysis:

  • Compare results across species (e.g., C. elegans csnk-1 vs. human CSNK1G2)

  • Test if human orthologs can functionally replace C. elegans proteins

How should CSNK1G3 gene knockout experiments be designed and validated?

For CSNK1G3 gene knockout studies:

• CRISPR-Cas9 approach:

  • Design sgRNAs targeting specific exons of CSNK1G3

  • Note that targeting specific regions may yield different phenotypes (e.g., targeting exon 12 which encodes the C-terminal region versus targeting kinase domain-encoding exons)

• Validation steps:

  • PCR verification of genomic DNA

  • RT-PCR to confirm altered mRNA processing

  • Western blot to confirm absence of protein

• Protocol considerations from published methods :

  • For PCR amplification of CSNK1G3:

    Reagent	Final Concentration	Amount
    5× PrimeSTAR GXL Buffer	1×	10 μL
    dNTP Mixture (2.5 mM each)	200 μM each	4 μL
    Sense primer (20 μM)	200 nM	0.5 μL
    Antisense primer (20 μM)	200 nM	0.5 μL
    cDNA solution	N/A	0.5 μL
    PrimeSTAR GXL DNA Polymerase	N/A	1 μL
    H2O	N/A	33.5 μL
    Total	N/A	50 μL

• Phenotypic analysis:

  • Compare with knockout/knockdown of other CSNK1G family members

  • Consider compensatory mechanisms among family members

What are the optimal conditions for immunoprecipitation using CSNK1G antibodies?

For successful immunoprecipitation:

• Antibody selection:

  • Use antibodies specifically validated for IP (e.g., CSNK1G1 polyclonal antibody 16384-1-AP)

  • Recommended dilution: 0.5-4.0 μg for 1.0-3.0 mg of total protein lysate

• Lysis buffer optimization:

  • For membrane-associated CSNK1G proteins, include appropriate detergents

  • Include phosphatase inhibitors to preserve phosphorylation status

  • Consider native versus denaturing conditions based on your research question

• Elution strategies:

  • Antigenic peptide elution (0.5 mg/ml for 6 hours) preserves antibody for reuse

  • Direct boiling in 1× SDS loading buffer for maximum recovery

• Verification approaches:

  • Reverse immunoprecipitation (e.g., if examining CSNK1G-RIPK3 interaction, immunoprecipitate with anti-RIPK3 and detect CSNK1G)

  • Include appropriate negative controls (e.g., IgG control, knockout samples)

How can I differentiate between the three CSNK1G isoforms in experimental settings?

To distinguish between CSNK1G1, CSNK1G2, and CSNK1G3:

• Antibody specificity:

  • Choose antibodies targeting unique regions of each isoform

  • Validate cross-reactivity using overexpression systems

  • Note that CSNK1G2, but not its closest family members CSNK1G1 and CSNK1G3, showed potent suppression of RIPK3 kinase activity

• RNA-level discrimination:

  • Design isoform-specific PCR primers

  • Use qRT-PCR to quantify individual isoform expression levels

• Functional approaches:

  • Perform isoform-specific knockdowns

  • Assess complementation capacity by expressing one isoform in cells depleted of another

• Tissue distribution profiling:

  • Leverage differential expression patterns (e.g., CSNK1G2's high expression in testis)

  • Use IHC to map isoform localization in tissue sections

What controls are essential when studying phosphorylation events mediated by CSNK1G proteins?

When investigating CSNK1G-mediated phosphorylation:

• Kinase activity controls:

  • Include kinase-dead mutants (e.g., CSNK1G2(K75A) and CSNK1G2(D165N))

  • Use casein kinase inhibitors as negative controls

• Substrate validation:

  • Generate phospho-site mutants of the putative substrate

  • Perform in vitro kinase assays with purified components

• Phospho-specific antibody controls:

  • Treatment with lambda phosphatase to remove phosphorylation

  • Use phospho-mimetic and phospho-dead mutants

• Auto-phosphorylation analysis:

  • Monitor CSNK1G2 auto-phosphorylation at serine 211/threonine 215 sites in its C-terminal domain, which triggers binding to RIPK3

How should experiments be designed to investigate CSNK1G's role in tissue-specific aging processes?

Based on the CSNK1G2 testis aging model:

• Longitudinal study design:

  • Compare tissues at different age points

  • For testis aging studies, examine animals at 3, 6, 12, and 18+ months

• Genetic approach options:

  • Generate tissue-specific conditional knockouts to avoid developmental effects

  • Consider double knockout with interacting partners (e.g., CSNK1G2/RIPK3 double knockout)

• Pharmacological interventions:

  • RIPK1 kinase inhibitor-containing diet can rescue CSNK1G2-knockout phenotypes

  • Test timing of intervention (preventative vs. therapeutic)

• Translational considerations:

  • Compare findings in mouse models to human tissues

  • For testis aging, phospho-MLKL was observed in testis of old (>80 years) but not young men

• Readouts to include:

  • Necroptosis markers (phospho-MLKL)

  • Tissue-specific functional parameters

  • Histological assessment of tissue integrity

What approaches are recommended for reconciling contradictory findings about CSNK1G functions across different experimental systems?

When facing contradictory results:

• System-specific differences analysis:

  • Compare in vitro cell line data with in vivo animal models

  • Consider tissue-specific functions (e.g., CSNK1G2's testis-specific role)

• Isoform-specific functions:

  • Different CSNK1G isoforms may have distinct roles

  • Note that CSNK1G2, but not CSNK1G1 or CSNK1G3, potently suppresses RIPK3

• Context-dependent activity:

  • Examine regulatory mechanisms under different conditions

  • Consider post-translational modifications affecting activity

• Methodological reconciliation:

  • Different knockout strategies may affect different protein domains

  • sgRNAs targeting exon 12 of CSNK1G3 versus those targeting kinase domain-encoding exons may yield different phenotypes

• Cross-species conservation analysis:

  • Compare functions between orthologs (e.g., C. elegans CSNK-1 versus human CSNK1G2)

  • Evolutionary conservation may indicate core functions